ArchiMed
ArchiMed is an independent asset management company with offices in New York, Lyon, Singapore and Tokyo, founded in 2014, that acts as a strategic and financial partner in the healthcare industries, mainly in Europe and the United States.
- Investment date
- 2021
In 2025
At end-2025, Peugeot Invest had co-invested in several companies alongside the Med Platform I and II funds and its partner ArchiMed.
These companies include: (i) Prollenium (a medical aesthetics company specialised in the research and manufacture of hyaluronic acid dermal fillers – investment made in 2021); (ii) Suanfarma (manufacturer and distributor of pharmaceutical and nutraceutical products – investment made in 2021); (iii) Carso (a leader in the French testing services market – investment made in 2021); and (iv) Natus (a US medtech specialised in solutions for diagnosing and treating disorders affecting the brain and sensory nervous systems – investment made in 2022).
(1) Commitments made in addition to the commitments to the Med Platform I and II, Med III and Med Rise funds.
Key figures
- Amount committed:
- € 42 million (1)